Preimplantation Genetic Testing Market - Global Forecast 2025-2032

The preimplantation genetic testing market is undergoing significant transformation, influenced by evolving diagnostics and regulatory frameworks. Senior decision-makers must access reliable, up-to-date market insights to inform agile strategies and maintain an edge in a shifting global healthcare landscape.

Market Snapshot: Preimplantation Genetic Testing Market Growth and Trends

The preimplantation genetic testing market is valued at USD 780.19 million in 2024, rising steadily to USD 873.74 million in 2025, with projections reaching USD 2.00 billion by 2032 and a CAGR of 12.55%. Rapid growth is catalyzed by advanced genomic technologies, a growing preference for assisted reproductive solutions, and evolving policy landscapes. Across North America, Europe, Asia Pacific, and key global regions, laboratories and clinics are redesigning their procurement and distribution practices to leverage new precision diagnostic capabilities. These adaptations require recalibration of operational models to meet heterogeneous clinical requirements and align with the latest regulatory demands and shifting supply networks.

Scope & Segmentation of the Preimplantation Genetic Testing Market

This market research report segments and analyzes the preimplantation genetic testing market to empower decision-makers with strategic visibility:

• Testing Type: Includes PGT-A for aneuploidy assessment, PGT-M for monogenic disorder detection, and PGT-SR to identify structural genetic rearrangements commonly encountered in clinical settings.
• Test Type: Covers solutions such as preimplantation genetic diagnosis for known conditions and preimplantation genetic screening for broader embryo evaluation.
• Technology Type: Focuses on technologies like comparative genomic hybridization, fluorescent in-situ hybridization, next-generation sequencing, PCR-based testing, and single-nucleotide polymorphism analysis—each providing distinct clinical and operational advantages.
• Offering: Spans instruments, reagents and consumables, and dedicated software to support lab workflows and ensure testing accuracy.
• End User: Addresses the needs of diagnostic laboratories, fertility clinics, hospitals, and research institutes, recognizing differing priorities and buying cycles.
• Region: Analyzes Americas (including the United States, Canada, and major Latin American economies), Europe (United Kingdom, Germany, France, and others), the Middle East (notably UAE and Saudi Arabia), Africa (with countries such as South Africa and Kenya), and Asia-Pacific (including China, India, Japan, and Australia), reflecting unique regulatory and supply chain dynamics in each.
• Companies: Profiles a competitive landscape that includes Abbott Laboratories, Agilent Technologies, Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International, F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Invicta Genetics, Invitae Corporation, Juno Genetics US, Laboratory Corporation of America Holdings, MedGenome Labs, Merck KGaA, Natera, NextGen Genetics Holdings, Ovation Fertility, PacGenomics, PerkinElmer, Progyny, Qiagen, Quest Diagnostics, Reproductive Genetic Innovations, SEQUENCE46, Sysmex Corporation, Takara Bio, The Cooper Companies, Thermo Fisher Scientific, Vitrolife Sweden, Yikon Genomics.

Key Takeaways for Senior Decision-Makers

• Emerging molecular testing platforms, especially next-generation sequencing and SNP arrays, are expanding embryo analysis capabilities and deepening clinical insight for providers and patients.
• Collaboration across laboratory, clinical, and counseling professionals plays a pivotal role in advancing noninvasive approaches and increasing process efficiency in fertility care.
• Artificial intelligence is increasingly utilized to optimize embryo selection, supporting more consistent outcomes and minimizing subjectivity in clinical decisions.
• Industry partnerships and acquisitions are vital for co-developing genetic testing solutions, encouraging automation, and enabling entry into new markets or geographies.
• Advanced automation and analytics investment empowers organizations to increase testing volume, enhance data reliability, and improve operational workflows in varied healthcare environments.
• Active engagement with regulatory changes positions companies for stronger compliance, better reimbursement alignment, and sustained competitiveness in evolving markets.

Impact of 2025 United States Trade Tariffs on Supply Chains and Cost Structures

The introduction of 2025 U.S. trade tariffs has affected labs and distributors reliant on imported reagents and instruments. Market leaders are responding by renegotiating supplier agreements, enhancing local manufacturing capabilities, and exploring new sourcing strategies. These measures require adapted inventory management, budgetary reassessment, and renegotiation of contracts to maintain business stability. Nearshoring, building in-house reagent production, and improving supply chain continuity have emerged as key responses to these external pressures.

Methodology & Data Sources

Analysis for this report is informed by expert interviews, comprehensive reviews of peer-reviewed literature, regulatory records, and device approvals. All quantitative and qualitative findings are verified through triangulation and validated using device performance data. Scenario planning and value chain mapping ensure data integrity and objective insights throughout the study.

Why This Report Matters

• Enables senior executives to anticipate technology developments and understand granular regional market trends for more reliable resource and strategy planning.
• Detailed segmentation and policy monitoring inform decisions on business continuity, compliance, and risk management.
• Actionable recommendations offer clear guidance for innovation, optimizing operational efficiency, and successful market entry or geographic expansion.

Conclusion

Innovation, regulatory adaptation, and collaborative efforts are shaping the future of preimplantation genetic testing. This report equips senior leaders to confidently steer their organizations through industry transitions and capitalize on evolving market opportunities.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.